NEP
N-ethylpentedrone
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
NEP (N-ethylpentedrone) is a synthetic stimulant of the substituted cathinone class. It is the N-ethyl homolog of pentedrone, distinguished by a substantially longer duration. It blocks the brain's clearance of dopamine and norepinephrine, producing stimulant arousal without the emotional warmth of serotonin-active compounds.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
cocaine, amphetamine, methamphetamine +2 morecocaine, amphetamine, methamphetamine, pentedrone, n-ethylhexedrone show less
NEP was created in the early 2010s by modifying pentedrone's structure to sidestep existing drug laws. First detected in a European police seizure in 2013,[3] it spread online as a research chemical before appearing in dozens of Polish fatal poisonings and a severe Belgian ICU admission.[4] As of 2026, it remains unscheduled in the United States; the EU published its formal risk assessment in 2025.
Subjective effects include euphoria, increased energy, appetite suppression, heightened focus, and wakefulness. The experience is a functional stimulant drive — clean arousal without emotional warmth, closer to cocaine in character than to empathogenic cathinones like mephedrone.[5] Anxiety, paranoia, and a strong compulsive compulsive redosing urge are characteristic unwanted effects.
NEP carries high abuse liability — repeated use rewires the brain's reward circuits, intensifying the urge to redose while reducing the pleasure obtained.[6] Overdose has caused muscle breakdown, kidney failure, and coma; combining it with stimulants or MAOIs sharply raises cardiovascular risk. The evidence base is extremely thin — current understanding rests on one clinical case, one mouse study, and structural analogy to related compounds.
History[edit]
Discovery
NEP was created as a structural modification of pentedrone to produce a compound not covered by existing cathinone laws. No academic publication documents the original synthesis or inventor.citation needed It was first identified through a European police seizure in 2013,[3] with detection in the United States following in 2014.citation needed
Proliferation
Through the mid-2010s NEP circulated online as a white crystalline powder.[5][7] By 2022 it ranked among the most detected cathinones in fatal poisoning cases in Poland, identified in blood from 26 fatal and 2 non-fatal cases.[7] Severe ICU toxicity was documented in Belgium and use in a drug-facilitated sexual assault in France.[4][5]
Regulatory response
The DEA placed related cathinones in Schedule I in June 2022, but NEP was not included.[8] The EU published its formal risk report on NEP in June 2025.[3] A DEA-commissioned study the same year classified NEP's abuse potential as comparable to cocaine and methamphetamine.[9]
The name NEP derives from N-Ethylpentedrone, following abbreviation conventions common among synthetic cathinones. It also appears in forensic literature as NEPD, α-EAPP, and α-ethylaminovalerophenone.[10] NEP has appeared in chemsex settings, where its stimulant profile without entactogenic properties positions it as a utilitarian stimulant rather than a social euphoriant.[5]
Chemistry[edit]
Structural class
NEP belongs to the substituted cathinone family — β-keto amphetamines built around a phenyl ring bonded to a ketone group.
It is the direct N-ethyl homolog of pentedrone and one chain carbon shorter than N-ethylhexedrone.[2] Its molecular formula is C₁₃H₁₉NO (205.30 g/mol), and its moderate fat-solubility allows adequate passage through the blood-brain barrier.[10]
Pharmacology[edit]
Mechanism of action
NEP is classed as a norepinephrine-dopamine reuptake inhibitor (NDRI) — it blocks the transporters that clear dopamine and norepinephrine from the synapse without triggering release of stored monoamines. This classification rests on structural analogy: pentedrone was directly characterized as a non-releasing uptake inhibitor,[1] and N-ethylhexedrone showed potent inhibition of the same transporters with negligible serotonin activity.[2] No direct measurements for NEP itself have been published.
Pharmacokinetics
No formal human pharmacokinetic studies exist. The primary breakdown pathway is N-deethylation, with a secondary carbonyl reduction route;[11] key metabolites have been confirmed in human urine after 20–40 mg doses given intranasally or orally.[12] One Belgian case report found blood concentrations above 2,000 ng/mL with no measurable decline over 17 hours, suggesting an unusually long persistence in the body.[4]
Detection
NEP shares a metabolite with Pentedrone and α-PVP, complicating forensic identification.[13] Standard clinical drug screens show poor cross-reactivity with synthetic cathinones including NEP, producing frequent false negatives.[14] Confirmatory identification requires advanced analytical methods such as LC-MS/MS.[12][4]
Neuroscience[edit]
Where it acts
By blocking dopamine reuptake, NEP extends dopamine signaling in the brain's primary reward hub, producing euphoria and motivational drive.[15][16] Simultaneously blocking norepinephrine reuptake drives the arousal and cardiovascular activation that accompany the stimulant experience. Repeated exposure in mice builds up a molecular marker in the striatum — a region central to motivation — that persists for weeks and promotes compulsive drug-seeking.[6]
Why it matters
NEP's high selectivity for dopamine over serotonin creates a lopsided pattern: it amplifies the wanting — the motivational compulsive redosing urge — more than the liking — the actual pleasure.[15] Repeated exposure also progressively amplifies the stimulant drive while depleting baseline dopamine.[6] The result is escalating craving alongside diminishing reward — the neurobiological engine of binge use.
Key unknowns include whether NEP damages dopamine or norepinephrine neurons at recreational doses, and how its two mirror-image molecular forms differ in effect. The compound's prolonged plasma persistence — exceeding 17 hours at high concentrations in one case[4] — may reflect slow metabolism, extensive tissue distribution, or continued absorption, a question critical for overdose management.
Subjective Effects[edit]
NEP produces a focused, utilitarian stimulant experience. The feeling is arousal and drive without emotional warmth — concentration sharpens, energy rises, and the urge to keep going builds steadily. The experience lacks the qualitative emotional shifts seen with serotonin-active compounds.[5]
Mechanistically closest to cocaine — pure reuptake inhibitor without monoamine release — but substantially longer-lasting.[17] Compared to mephedrone or methylone, NEP lacks empathogenic warmth; only a small minority of users report anything MDMA-like.[5]
Effect Grid
At common doses (approximately 20-40 mg intranasal), the full stimulant profile emerges: pronounced euphoria, significant thought acceleration, strong motivation enhancement, and increased confidence. Focus enhancement is prominent. Compulsive redosing urge becomes a notable feature at this range, consistent with the DAT-dominant mechanism.
Physically, tachycardia is evident, appetite is markedly suppressed, bruxism is common, and excessive sweating may occur. Vasoconstriction produces cold extremities. Duration of stimulation extends for several hours, and sleep is impossible during the active phase.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing acceleration · Visual acuity enhancement · Tinnitus · Shadow people
Dry mouth · Insomnia · Pupil dilation · Restlessness · Dehydration sensation · Excessive sweating · Heart rate perception changes · Muscle tension · Physical fatigue · Respiratory stimulation · Spontaneous body sensations · Bruxism · Headache · Tingling / electric sensations · Trembling · Sexual arousal enhancement · Dizziness · Nausea · Tactile euphoria · Vibrations / buzzing · Sexual arousal suppression · Increased urination · Involuntary body movements · Motor control impairment · Nystagmus (eye wobbles) · Vomiting · Tactile hallucination
Restlessness · Dehydration sensation · Excessive sweating · Heart rate perception changes · Muscle tension · Physical fatigue · Respiratory stimulation · Spontaneous body sensations · Bruxism · Headache · Tingling / electric sensations · Trembling · Sexual arousal enhancement · Dizziness · Nausea · Tactile euphoria · Vibrations / buzzing · Sexual arousal suppression · Increased urination · Involuntary body movements · Nystagmus (eye wobbles) · Vomiting · Tactile hallucination
Immersion enhancement · Multiple thought streams · Novelty enhancement · Pattern recognition enhancement · Analysis enhancement · Focus enhancement · Motivation enhancement · Information processing enhancement · Motivation suppression · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Thought connectivity · Thought loops · Thought organization · Creativity enhancement · Humor enhancement · Language enhancement · Cognitive impairment · Confusion · Focus suppression · Thought disorganization · Thought deceleration
Analysis enhancement · Focus enhancement · Motivation enhancement · Information processing enhancement · Motivation suppression · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Thought connectivity · Thought loops · Thought organization · Creativity enhancement · Humor enhancement · Language enhancement · Cognitive impairment · Confusion · Focus suppression · Thought disorganization · Thought deceleration
Anhedonia · Dysphoria · Emotional enhancement · Emotional lability · Empathy enhancement
Empathy enhancement
Sociability enhancement · Social connection · Flow state · Emotional susceptibility · Sociability suppression · Depersonalization · Derealization
Sociability suppression · Depersonalization · Derealization
Timeline
First effects emerge 15–45 minutes after oral ingestion: subtle mood lift, mild alertness increase, and slight peripheral stimulation.
Stimulation builds steadily. Thought acceleration, tachycardia, and appetite suppression become apparent. Nausea is possible during this phase.
Full stimulant profile: euphoria, focus enhancement, motivation, marked appetite suppression, tachycardia, bruxism. Oral onset is slower but peak may be more sustained than insufflated.
Diminishing euphoria with persistent wakefulness and cardiovascular stimulation. Compulsive redosing urge may be less acute than with insufflation due to the slower onset kinetics.
Slow return toward baseline. Residual wakefulness and restlessness outlast subjective stimulation. Sleep remains difficult.
Residual fatigue, low mood, appetite disturbance, and difficulty concentrating may persist for 8–16 hours after effects resolve. Given the prolonged plasma persistence documented for NEP, subclinical effects may outlast subjective awareness.
⚠ Do not drive or operate machinery until after a full night of restorative sleep following complete resolution of all subjective effects.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- cocaine · amphetamine · methamphetamine
Toxicity
Acute toxicity
No lethal dose has been established for NEP in any species, and no therapeutic index exists.safety citation needed
The most severe documented case describes a patient who developed agitation, paranoid delusions, racing heart, fever, muscle breakdown, kidney failure, metabolic acidosis, and coma after intranasal use — requiring ICU admission and three days on a ventilator.[4] Full recovery was achieved with supportive care.[4]
Heart and circulation
Rapid heart rate is confirmed in clinical reports.[4] High blood pressure is expected from norepinephrine reuptake inhibitor but has not been specifically documented for NEP. Heart rhythm disturbances have not been studied.safety citation needed
Kidney and muscle damage
Muscle breakdown and acute kidney failure are documented in a single case.[4] Likely contributors include heat-induced muscle damage and vasoconstriction reducing blood flow to the kidneys, though the mechanism is not established.inferred
Temperature dysregulation
Fever is documented in the clinical case,[4] and mild temperature elevation occurs in mice at higher doses.[6]
Fatality data
NEP was detected in blood from 26 fatal and 2 non-fatal poisoning cases in Poland.[7] All fatalities involved multiple substances — NEP alone could not be isolated as cause of death. In a broader series of 96 NPS-related deaths, synthetic cathinones appeared in 67% of cases, with alcohol co-detected in 27.[18]
No antidote exists for synthetic cathinone poisoning. Treatment is supportive, extrapolated from cocaine and amphetamine overdose protocols.[16] Muscle breakdown requires aggressive intravenous hydration; dialysis may be needed.[4]
Psychological risks
Severe agitation, paranoid delusions, and paranoia are documented in acute overdose.[4] Mouse withdrawal data show increased aggression, impaired social behavior, and loss of the anxiety-reducing effect seen during acute exposure[6] — if these findings translate to humans, withdrawal may involve irritability, sociability suppression, and anxiety.
High doses or binge use can produce paranoia, hallucinations, and delusional thinking.inferred
Tolerance & dependence
No human studies have assessed tolerance or dependence for NEP. Repeated dosing in mice builds up a molecular marker in the striatum — the most reliable indicator of addiction vulnerability — alongside depleted dopamine and elevated stress hormones during withdrawal.[6]
Dopamine-selective cathinones carry the highest addiction liability among cathinone pharmacological groups,[17][15] and NEP is characterized as high abuse potential in the forensic literature.[5] Tolerance onset and reset timelines have not been established.safety citation needed
Drug interactions
No NEP-specific interaction studies have been published. All assessments below are based on its pharmacological class.
Stimulant combinations
Combining NEP with other stimulants (Cocaine, amphetamines, other cathinones) adds cardiovascular load — dangerous blood pressure elevation, rapid heart rate, and overheating — and increases seizure risk.
Serotonergic combinations
Although NEP has minimal serotonin activity, combining it with serotonin-active substances (MDMA, mephedrone) or serotonin reuptake inhibitors risks cardiovascular overstimulation and overheating. Combining with tramadol carries theoretical risk of serotonin syndrome — a potentially life-threatening overheating and seizure response.safety citation needed
Alcohol
Approximately 95% of synthetic cathinone users co-use alcohol.[19] In animal studies, alcohol-cathinone combinations roughly double brain toxicity,[19] and alcohol was co-detected in 27 of 96 NPS-related fatalities.[18]
Enzyme-mediated interactions
NEP's liver enzyme metabolism profile is uncharacterized.[11] If CYP2D6 is involved, drugs that inhibit this enzyme — including fluoxetine, paroxetine, and bupropion — could raise NEP blood levels.inferred
Contraindications
Heart conditions — high blood pressure, coronary artery disease, rhythm disorders, structural heart disease — represent absolute contraindications given confirmed rapid heart rate[4] and expected cardiovascular stress from norepinephrine accumulation. Kidney impairment is a relative contraindication given documented muscle breakdown and kidney failure.[4]
Psychotic disorders and bipolar disorder are relative contraindications; dopamine stimulation may trigger or worsen psychotic episodes, as shown by overdose-documented paranoia.[4] Seizure disorders carry theoretical risk from stimulant-driven lowering of the seizure threshold.inferred
Pregnancy and breastfeeding are absolute contraindications — no reproductive safety data exist, and stimulant effects on blood flow preclude safe use.safety citation needed Concurrent MAOI use is an absolute contraindication due to risk of dangerous blood pressure crisis from accumulated catecholamines.inferred
Harm Reduction[edit]
Forms & Identification
NEP is typically sold as a white crystalline powder and is visually indistinguishable from dozens of other synthetic cathinones.[5] Standard clinical drug screens frequently miss synthetic cathinones, returning false negatives even at high concentrations.[14] Reagent testing provides a first line of identification but cannot confirm purity or rule out contamination with other cathinones.
Any powder sold as NEP may contain a different cathinone with a different potency and risk profile. Start with the lowest plausible dose and wait for full onset before considering redosing.
Guidelines
- Test every batch with reagent kits before use; consider postal drug-checking services where available
- Weigh doses with a milligram-precision scale — never estimate by eye
- Choose oral administration over insufflation to reduce compulsive redosing urge and peak cardiovascular stress
- Set a firm dose limit and time limit before the session; write it down
- Stay hydrated but avoid overhydration — moderate, steady water intake
- Monitor body temperature; move to a cooler environment if overheating
- Have a sober companion present, especially at higher doses
- Avoid physical exertion in hot environments
- Do not combine with other stimulants, alcohol, or MAOIs
- Allow at least 24 hours between sessions to reduce cardiovascular and neurological strain
Set & Setting
NEP's dopamine-dominant profile means the balance between productive stimulation and anxious overstimulation is heavily influenced by environment and mental state. Physical settings with high temperatures or sustained physical activity increase the risk of overheating and muscle breakdown — both documented complications.[4]
The compulsive redosing urge is strongest with insufflation and in social or party settings. Having a predetermined dose limit and a sober companion reduces the likelihood of binge escalation. Solitary use removes external checks on escalation and delays recognition of medical emergencies.
Aftercare & integration. The stimulant comedown from NEP reflects temporary dopamine depletion. Low mood, fatigue, irritability, and difficulty concentrating are expected for 24–72 hours after use.
Prioritize sleep — avoid further stimulant use to "push through" fatigue. Eat nutrient-dense meals even if appetite is suppressed. Light physical activity and social contact can help restore baseline mood, but avoid intense exercise until body temperature, heart rate, and hydration have fully normalized.
If low mood persists beyond a week, or if the urge to redose dominates thinking between sessions, these are early signals of a developing use pattern that warrants professional support.
Recovery & Support
NEP's dopamine-selective mechanism and documented molecular brain changes predict a dependence pattern marked by strong cravings, compulsive redosing, and withdrawal characterized by low mood and irritability.[6]
Recognizing the pattern is the first step: escalating doses, shortening intervals between sessions, continued use despite negative consequences, and inability to adhere to self-imposed limits.
Professional support options include addiction counseling, cognitive behavioral therapy, and stimulant-specific recovery programs. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals in the United States.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
NEP emergencies are stimulant emergencies. Recognizing the line between uncomfortable and dangerous:
- Uncomfortable but manageable: anxiety, bruxism, mild nausea, elevated heart rate, restlessness
- Seek immediate help: chest pain, seizure, loss of consciousness, body temperature hot to the touch through clothing, persecutory delusions, severe confusion, inability to urinate (may signal kidney involvement)
Immediate steps:
- Call emergency services if any dangerous signs are present
- Move the person to a cool, quiet environment
- Remove excess clothing to aid cooling
- Offer small sips of water if conscious and alert
- Place in the recovery position if unconscious but breathing
- Do NOT restrain unless there is immediate danger of self-harm
- Do NOT induce vomiting
Tell the dispatcher: the substance name (NEP / synthetic cathinone), estimated amount and time of last dose, route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for synthetic cathinone overdose. All treatment is supportive.
Legal Status[edit]
NEP is not scheduled under UN international drug conventions; most jurisdictions rely on structural analog provisions or blanket psychoactive substance legislation rather than specific scheduling.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled (as of April 2026) | Not included in the June 2022 Schedule I placement of NEH and five other cathinones.[8] Prosecution possible under the Federal Analogue Act. DEA-commissioned abuse liability study published 2025[9] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Broadly banned since 26 May 2016. Not specifically named in the Misuse of Drugs Act 1971 |
| European Union | Subject to EU Early Warning System monitoring | EUDA published formal initial report in June 2025.[3] Individual member state scheduling varies |
| Sweden | Hälsofarlig vara (potentially harmful substance) | Controlled under Swedish public health legislationcitation needed |
| Japan | Designated stimulant analog | Controlled as a potentially harmful substancecitation needed |
| China | Controlled | Regulated under non-medical psychoactive substance provisionscitation needed |
Analog act considerations
In the United States, the Federal Analogue Act allows prosecution for substances substantially similar in chemical structure or pharmacological effect to a Schedule I or II controlled substance when intended for human consumption. NEP's structural similarity to N-ethylhexedrone (Schedule I since June 2022[8]) and published behavioral data confirming cocaine/methamphetamine-like effects[9] provide a strong basis for analog act prosecution.
Legal status changes frequently and varies by jurisdiction. This article reflects information available as of April 2026 and is not legal advice.
references
- [1] ^abSimmler LD, Rickli A, Hoener MC, Liechti ME (2014) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones — Neuropharmacology doi:10.1016/j.neuropharm.2013.11.008
- [2] ^abcKolaczynska KE, Thomann J, Hoener MC, Liechti ME (2021) The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative. — International journal of molecular sciences doi:10.3390/ijms22158277
- [3]
- [4]
- [5]
- [6]